ArticleHealth and quality of life outcomes2021
The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings.
Article in Health and quality of life outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Correlation of frailty assessment metrics in one-year follow-up of aged care residents: a sub-study of a randomised controlled trial.Aging clinical and experimental research · 2023Trial
- Comparative performance of the EQ-5D-5L, EQ-HWB, and PROMIS-10 in screening for history of anxiety and depression in the general adult population in 15 countries.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Agreement between the EQ-5D-5L anxiety/depression dimension and GAD-7/PHQ-9 for psychological distress assessment in patients with hematologic malignancies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Comparing the measurement properties of the EQ-5D-Y-3L and EQ-5D-3L in a general population sample of adults.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- A systematic review of economic evaluations of community-based healthcare interventions for neurodisability management.Health economics review · 2026Review
- Anxiety and/or depression in heart failure across the ejection fraction spectrum: the SwedeHF registry.ESC heart failure · 2026Article
- In-depth psychometric evaluation of the PsychQOL questionnaire: factor structure and ROC analysis.Frontiers in psychology · 2026Article
- Article
- Alcohol Consumption and Health Outcomes Among Men in a Rural HIV-Endemic Cohort in South Africa.Wellcome open research · 2025Article
- Assessment of depressive disorders and states of anxiety in patients following cerebrovascular accidents in connection with health care provision.Central European journal of public health · 2024Article
- Health-related quality of life (HRQoL) loss associated with self-perceived anxiety/depression in seropositive rheumatoid arthritis.Clinical rheumatology · 2024Article
- The performance relationship between the EQ-5D-5L composite "Anxiety/Depression" dimension and anxiety and depression symptoms in a large, general population sample.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- Health-Related Quality of Life in Patients with Spinocerebellar Ataxia: a Validation Study of the EQ-5D-3L.Cerebellum (London, England) · 2024Article
- The burden of persistent symptom diagnoses in primary care patients: a cross-sectional study.Scandinavian journal of primary health care · 2024Article
- Health-related quality of life among people who inject drugs in Australia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Observational
- Examining the psychometric properties of a split version of the EQ-5D-5L anxiety/depression dimension in patients with anxiety and/or depression.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023Article
- Symptoms of anxiety and depression in patients with persistent asthma: a cross-sectional analysis of the INSPIRERS studies.BMJ open · 2023Article
- Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients.Biomolecules · 2023Article
- Risk factors for incident falls in Singaporean community-dwelling adult men and women: a prospective cohort study.BMJ open · 2023Article
- Health-related quality of life among Indian population: The EQ-5D population norms for India.Journal of global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo examine the performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings compared to other patient-reported screening tools.
methodsData from a prospective cohort of patients discharged from general internal medicine wards from two hospitals in Edmonton, Alberta were used in this study. Two waves of measurements (discharge and 90-days post-discharge) were analyzed. The performance of the EQ-5D-3L was compared to other self-report screening tools: Generalized Anxiety Disorder 2-item questionnaire was used to categorize anxiety symptoms into absent (< 3) and present (≥ 3), and the Patient Health Questionnaire 9-items was used to categorize depressive symptoms by two severity cut-points: no (< 10) vs. mild (≥ 10), and no (< 15) vs. moderate-severe (≥ 15). Performance of EQ-5D-3L in screening for anxiety and depressive symptoms was evaluated using receiver operating curve (ROC) analysis.
resultsAverage age of participants (n = 493) was 62.9 years (SD 18.6); 51% were female. At discharge, 30.0% screened positive for mild and 12.8% for moderate-severe depressive symptoms, while 27.6% screened positive for anxiety symptoms. For co-morbid symptoms, 17.1% screened positive for anxiety and any depressive symptoms, while 10.8% for anxiety and moderate-severe depressive symptoms. While the EQ-5D-3L had limited screening ability in hospital, the anxiety/depression dimension performed well in the community setting (90-days post-discharge) in screening for anxiety (area under ROC 0.79), depressive symptoms (any: 0.78, moderate-severe: 0.84), and a combination of both (any: 0.86; moderate-severe: 0.91).
conclusionsThe EQ-5D-3L anxiety/depression dimension could be a useful tool in screening for anxiety and depressive symptoms in community settings compared to other self-report screening tools. The usefulness of the EQ-5D-3L as a screening tool in other settings and populations is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.